CCEL vs VCEL vs FATE vs NTLA vs EDIT

For growth investors, Intellia Therapeutics, Inc.

(NTLA) is the stronger pick with 16. 9% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). Cryo-Cell International, Inc. (CCEL) offers the better valuation at 69. 0x trailing P/E, making it the more compelling value choice. Analysts rate Vericel Corporation (VCEL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cryo-Cell International, Inc.

(CCEL) is the cheapest at 69. 0x versus Vericel Corporation at 109. 8x.

Over the past 5 years, Vericel Corporation (VCEL) delivered a total return of -33.

3%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: VCEL returned +1206% versus EDIT's -90. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cryo-Cell International, Inc.

(CCEL) is the lower-risk stock at 0. 35β versus Editas Medicine, Inc. 's 2. 52β — meaning EDIT is approximately 617% more volatile than CCEL relative to the S&P 500. On balance sheet safety, Intellia Therapeutics, Inc. (NTLA) carries a lower debt/equity ratio of 14% versus 66% for Editas Medicine, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intellia Therapeutics, Inc.

(NTLA) is pulling ahead at 16. 9% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Cryo-Cell International, Inc. grew EPS 104. 4% year-over-year, compared to 27. 4% for Intellia Therapeutics, Inc.. Over a 3-year CAGR, VCEL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vericel Corporation (VCEL) is the more profitable company, earning 6.

0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCEL leads at 10. 9% versus -22. 2% for FATE. At the gross margin level — before operating expenses — NTLA leads at 76. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 1525.

5% to $39. 50.

In this comparison, CCEL (7.

1% yield) pays a dividend. VCEL, FATE, NTLA, EDIT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cryo-Cell International, Inc.

(CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), 7. 1% yield). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCEL: +61. 3%, EDIT: -90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CCEL is a small-cap income-oriented stock; VCEL is a small-cap high-growth stock; FATE is a small-cap quality compounder stock; NTLA is a small-cap high-growth stock; EDIT is a small-cap quality compounder stock. CCEL pays a dividend while VCEL, FATE, NTLA, EDIT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.